Skip to main content
Fig. 1 | Journal of Ovarian Research

Fig. 1

From: Bevacizumab confers significant improvements in survival for ovarian cancer patients with low miR-25 expression and high miR-142 expression

Fig. 1

The association of miR-25 and miR-142 expression with OS. A MiR-25 was associated with increased PFS (HR: 0.59, 95%CI: 0.40–0.85, Log-rank P = 0.005) in GSE140082 dataset; B MiR-25 was associated with extended OS (HR: 0.42, 95%CI: 0.23–0.76, Log-rank P = 0.004) in GSE140082 dataset; C There was no significant correlation between miR-142 expression and PFS (HR: 1.05, 95%CI: 0.78–1.41, Log-rank P = 0.746) in GSE140082 dataset; D MiR-142 was associated with reduced OS (HR: 1.56, 95%CI: 1.00–2.43, Log-rank P = 0.049) in GSE140082 dataset

Back to article page